Company intelligence

Assort Health

As of June 24, 2026, Assort Health was last valued at $1.2B (June 2026 Series C) and has raised at least $196M in equity across 2 sourced funding rounds.

Assort Health builds AI voice agents that automate patient access workflows for healthcare organizations, including scheduling, intake, referrals, and insurance verification.

Healthcare AISan Francisco, California, USAFounded 2023Founders: Jon Wang, Jeffery LiuWebsite ↗See connections →Compare with Anthropic
Last verified Jul 30, 2026

Assort Health at a glance

As of
Latest valuation
$1.2B[1]
Series C · June 2026
Equity raised
$196M[2]
Across 2 sourced roundsDerived
Lead investors
Menlo Ventures, Lightspeed Venture Partners[3]
Across 2 sourced rounds
  1. [1] Latest valuation: PR Newswire, June 24, 2026
  2. [2] Equity raised: Sum of the 2 sourced equity rounds in the funding history below (debt, tender offers and rumored rounds excluded), June 24, 2026
  3. [3] Lead investors: PR Newswire, June 24, 2026

What Assort Health does

Assort Health builds AI voice agents that handle patient calls for medical practices, covering scheduling, intake, referrals, medication refills, eligibility checks and payments.[1] Jeff Liu and Jon Wang founded the San Francisco company in 2023 and serve as co-CEOs.[2],[3],[1] Its agents are built for specific medical specialties.[2] Menlo partner JP Sanday joined the board, and partner Matt Murphy became a board observer.[1] The company says its agents have handled more than 190 million patient interactions.[1] Its in-house model, Synapse, learns specialty workflows across deployments and generates the tests and simulations each new deployment must pass.[1] The platform integrates with electronic health record systems including Epic and Athena.[1]

Assort Health profile

written 2026-10-24

Assort Health sells AI voice agents for patient access and raised a $120 million Series C at a $1.2 billion valuation in June 2026.

What Assort Health does

Assort Health sells AI voice agents that answer patient calls for medical practices and health systems, and it calls itself the most widely used AI agents platform for the patient journey. The June 2026 release lists scheduling, intake forms, referrals, document processing, medication refills, real-time insurance eligibility, lab requests and payments as the workflows the platform covers.[1],[2]

Assort Health's platform has four products. Concierge handles inbound calls, triage, scheduling and intake in any language. Activate reaches patients proactively to close referral loops, act on care gaps and recover no-shows. Orchestrate runs the operational work behind each visit and writes it back to the electronic health record. Empower is a copilot for staff. A layer the company calls Patient Journey Memory links them, and a proprietary model called Synapse learns specialty workflows across deployments.[1]

Assort Health says its platform integrates natively with major EHR and practice management systems, naming Epic and Athena. Assort Health's practice customers report a 5% lift in appointment volume, a 115% increase in labor capacity and a 4.3 out of 5 patient satisfaction score, according to the company's own release. These are company-reported figures without a named study behind them.[1]

History

Assort Health was founded in 2023 by Jeff Liu and Jon Wang, who Fortune reported spent two years getting to know the healthcare system before the startup picked up steam. The company is based in San Francisco, the dateline on its releases.[3],[1]

Assort Health raised a $22 million Series A in April 2025 and a $76 million Series B in September 2025, when it also launched a platform it called Assort OS. Its June 2026 Series C came with an expansion from physician groups into health systems, with John Muir Health named as one partner.[3],[4],[1]

Assort Health followed with a primary care push in September 2026 and a codevelopment deal with the practice software vendor Nextech in October 2026, both covered below.[5],[6]

Funding

Assort Health raised a $120 million Series C led by Menlo Ventures at a valuation of $1.2 billion, announced on June 25, 2026, and says it has now raised more than $222 million. Lightspeed Venture Partners, Felicis, First Round Capital, Chemistry, Joe Montana, Tau Ventures and Quiet Capital also took part. The release does not say whether the $1.2 billion is a pre-money or post-money figure.[1]

Assort Health closed a $76 million Series B on September 30, 2025, led by Lightspeed Venture Partners with Felicis, First Round Capital, Chemistry, A*, Liquid2 and Quiet Capital. Fortune, which broke the news, put total capital raised at $102 million at that point.[4],[3]

Assort Health's $22 million Series A was led by First Round and Chemistry, according to Fortune, which reported it ahead of the Series B. The company has not disclosed revenue, so the 20x growth claim cannot be sized.[3],[1]

People

Jeff Liu and Jon Wang are Assort Health's founders and co-CEOs. Liu appears as Jeffery Liu in the company's releases, and both are quoted in them as founder and co-CEO.[1],[4],[3]

Assort Health added JP Sanday of Menlo Ventures to its board with the Series C, and Menlo's Matt Murphy serves as a board observer. In the Series B, the company said Galym Imanbayev of Lightspeed Venture Partners would join the board and Paul Ricci, founding CEO of Nuance, would join as a board advisor. No headcount has been disclosed.[1],[4]

Customers and partners

Assort Health names Boston Bone and Joint Institute, MDCS Dermatology and John Muir Health among customers in its Series C release, and Annapolis Internal Medicine in its Series B release. A September 2026 release adds Family Practice Associates of Lexington, Pediatric Associates of Southwest Missouri, Voyage Healthcare, Middleton Family Medicine and Pediatrica Health Group.[1],[4],[5]

Assort Health said on September 24, 2026 that its agents support more than 1,300 primary care providers across family medicine, internal medicine and pediatrics, and that in those deployments it resolves 95% of patient access interactions that do not need a staff handoff. At Annapolis Internal Medicine, proactive outreach accounted for 61% of flu shot appointments across three clinics, and the practice cut hold times by 75%.[5]

Assort Health and Nextech announced on October 9, 2026 that they will codevelop a joint AI agent offering for Nextech's customers. The release says Assort's experience spans hundreds of healthcare deployments, including 40% of the Fortune 20 healthcare enterprises. At DuPage Ophthalmology, a Nextech practice, Assort handles roughly 500 patient calls a week, and the practice administrator said it saved more than 60% of call time.[6]

Is something wrong on this page?

Company Snapshot

Assort Health is a healthcare AI company, based in San Francisco, California, USA, founded 2023 by Jon Wang, Jeffery Liu.

Recent changes

  1. Jun 24, 2026Raised $120M Series C at a $1.2B valuation PR Newswire
  2. Jun 24, 2026New investor: Menlo Ventures PR Newswire
  3. Jun 24, 2026Assort Health Raises $120M Series C at a $1.2B Valuation for Healthcare AI Agents Pulse story
  4. Sep 30, 2025Raised $76M Series B PR Newswire
  5. Sep 30, 2025New investor: Lightspeed Venture Partners PR Newswire

Funding history

2 equity events · newest first · sources dated per row
DateRoundAmountValuationLead investorsSource
Jun 24, 2026Series C$120M$1.2Bpost-moneyPR Newswire
Sep 30, 2025Series B$76M—PR Newswire

Equity only. “Equity raised” above sums the rounds with a dated, linked source; rumored rounds, tender offers and secondary sales are listed but not counted, and debt financing is listed separately.

Funding timeline · 2 rounds · $196M tracked
$0.0M$67M$134M$76MSeries BSep 25$120MSeries CJun 26

How Assort Health has been funded

In September 2025 it closed a $76 million Series B led by Lightspeed Venture Partners, four months after its Series A, bringing total funding to $102 million.[3] In June 2026 Assort raised a $120 million Series C led by Menlo Ventures at a $1.2 billion valuation, with Lightspeed, Felicis, First Round Capital, Chemistry and Joe Montana participating.[1] The round brought total funding to more than $222 million.[1] It says revenue grew 20 times over the 15 months before the Series C.[1]

Investors

Latest Pulse

  1. Vertical AI Series A Rounds Are Quietly Getting BiggerA cluster of recent Series A and C rounds -- General Intuition's $320M, RunPod's $100M and Assort Health's $120M among them -- shows vertical AI applications commanding round sizes once reserved for infrastructure megadeals.→
  2. Assort Health Raises $120M Series C at a $1.2B Valuation for Healthcare AI AgentsAssort Health raised a $120 million Series C led by Menlo Ventures at a $1.2 billion post-money valuation, vaulting the patient-access automation startup into unicorn territory. Its AI agents handle scheduling, intake, referrals, document processing and front-desk support for healthcare providers -- one of the clearest examples of AI moving from chatbot demos to embedded, revenue-bearing clinical workflows.→
  3. Taktile Raises $110M Series C Led by Goldman Sachs for AI Decisioning in FinanceTaktile raised a $110 million Series C led by Goldman Sachs Alternatives to scale its AI decisioning platform, which lets banks and insurers automate underwriting, claims, fraud detection and anti-money-laundering workflows with human oversight. The round is a vote of confidence that regulated financial institutions will pay for AI that makes high-stakes decisions auditable rather than just faster.→

Coverage Timeline

newest first
  1. Jul 5, 2026FUNDINGVertical AI Series A Rounds Are Quietly Getting Bigger$650M+ combined across 4 vertical rounds→
  2. Jun 24, 2026FUNDINGAssort Health Raises $120M Series C at a $1.2B Valuation for Healthcare AI Agents$120M→

All Coverage

Related Companies

Assort Health FAQ

What is Assort Health's valuation?

In June 2026 Assort raised a $120 million Series C led by Menlo Ventures at a $1.2 billion valuation, with Lightspeed, Felicis, First Round Capital, Chemistry and Joe Montana participating.[1]

How much has Assort Health raised?

In September 2025 it closed a $76 million Series B led by Lightspeed Venture Partners, four months after its Series A, bringing total funding to $102 million.[3]

What does Assort Health do?

Assort Health builds AI voice agents that handle patient calls for medical practices, covering scheduling, intake, referrals, medication refills, eligibility checks and payments.[1]

Who invested in Assort Health?

Lead investors in Assort Health's sourced funding rounds include Menlo Ventures and Lightspeed Venture Partners. Per round: its June 2026 Series C was led by Menlo Ventures; its September 2025 Series B was led by Lightspeed Venture Partners.

References

researched 2026-10-23
  1. PR Newswire
  2. Fortune
  3. PR Newswire
Sources & methodologyshow
Where these figures come from

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data ·